Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update

Key Points

• Inventiva S.A. Sponsored ADR (NASDAQ:IVA) experienced a dramatic **increase in short interest** of 392.0% in July, rising from 7,500 shares to 36,900 shares.
• Institutional investors, including Wealth Enhancement Advisory Services LLC, **raised their stakes** in Inventiva by 54.5% in the second quarter, reflecting growing interest in the company.
• Inventiva's stock is currently trading at **$3.22**, with a one-year range fluctuating between **$1.53** and **$4.05**.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - ) was the target of a large increase in short interest in July. As of July 15th, there was short interest totaling 36,900 shares, anincreaseof392.0% from the June 30th total of 7,500 shares. Based on an average daily volume of 19,400 shares, the days-to-cover ratio is currently 1.9 days. Based on an average daily volume of 19,400 shares, the days-to-cover ratio is currently 1.9 days.

Institutional Investors Weigh In On Inventiva

An institutional investor recently raised its position in Inventiva stock. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) by 54.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,558 shares of the company's stock after acquiring an additional 5,843 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Inventiva were worth $50,000 at the end of the most recent quarter. Institutional investors own 19.06% of the company's stock.

Inventiva Stock Performance

Shares of Inventiva stock opened at $3.22 on Friday. Inventiva has a 1 year low of $1.53 and a 1 year high of $4.05. The firm's 50-day simple moving average is $3.28 and its 200-day simple moving average is $3.09.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.